Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI

British Journal of Cancer

Volumn 113, Issue 9, 2015, Pages 1282-1288

  Guo, J ^a   Glass, J O ^a   McCarville, M B ^a   Shulkin, B L ^a   Daryani, V M ^a   Stewart, C F ^a   Wu, J ^a   Mao, S ^a   Dwek, J R ^b   Fayad, L M ^c   Madewell, J E ^d   Navid, F ^a,e   Daw, N C ^a,d   Reddick, W E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG EXPOSURE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EVENT FREE SURVIVAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA VOLUME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR VASCULARIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; PROCEDURES;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; CHILD; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84946493879     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.351     Document Type: Article

References (38)

1. Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V (2014) Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. Am J Clin Oncol 37(4): 384-390.
2. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, Salduca N, Versari M, Smith KV (2001) Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 37(1): 32-38.
3. Bajpai J, Gamnagatti S, Kumar R, Sreenivas V, Sharma MC, Khan SA, Rastogi S, Malhotra A, Safaya R, Bakhshi S (2011) Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol 41(4): 441-450.
4. Bland JM, Altman DG (2004) The logrank test. BMJ 328(7447): 1073.
5. Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T-1-weighted MRI. Magn Reson Med 47(3): 601-606.
6. Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS, Koh JS, Yoo JY, Oh DH, Shin DS, Jeon DG (2009) Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med 50(9): 1435-1440.
7. Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B 34: 187-220.
8. Cox DR (1975) Partial likelihood. Biometrika 62: 269-276.
9. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC (2004) High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100(8): 1724-1733.
10. Cyran CC, Fu Y, Rogut V, Chaopathomkul B, Wendland MF, Shames DM, Brasch RC (2013) Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model. Acad Radiol 20(10): 1256-1263.
11. Delong ER, Delong DM, Clarkepearson DI (1988) Comparing the areas under 2 or more correlated receiver operating characteristic curves-A nonparametric approach. Biometrics 44(3): 837-845.
12. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13(13): 3942-3950.
13. Dyke JP, Panicek DM, Healey JH, Meyers PA, Huvos AG, Schwartz LH, Thaler HT, Tofts PS, Gorlick R, Koutcher JA, Ballon D (2003) Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228(1): 271-278.
14. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, Hoffer FA, Kaste SC, Jenkins JJ, Ortega Flores XC, Quintana J, Villarroel M, Daw NC (2012) Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer 118(15): 3776-3785.
15. Hawkins DS, Conrad 3rd EU, Butrynski JE, Schuetze SM, Eary JF (2009) [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115(15): 3519-3525.
16. Hoang BH, Dyke JP, Koutcher JA, Huvos AG, Mizobuchi H, Mazza BA, Gorlick R, Healey JH (2004) VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 426: 32-38.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
18. Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101: 14-18.
19. Jain RK (2005a) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(4 Suppl 3): 7-16.
20. Jain RK (2005b) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58-62.
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assn 53: 457-481.
22. Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, Grizzle WE, George JF, Buchsbaum DJ, Morgan DE, Zinn KR (2011) DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol 13(1): 94-103.
23. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32(6): 423-436.
24. Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Maelandsmo GM, Akslen LA, Gribbestad IS (2013) Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusionweighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging 38(5): 1043-1053.
25. Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, Jackson A, Watson Y, Davies K, Jayson GC (2006) Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 56(5): 993-1000.
26. Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TP, van Bruggen N (2010) Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Magn Reson Med 64(2): 408-417.
27. Reddick WE, Taylor JS, Fletcher BD (1999) Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10(3): 277-285.
28. Reddick WE, Wang S-C, Xiong X, Glass JO, Wu S, Kaste SC, Pratt CB, Meyer WH, Fletcher BD (2001) Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 91(12): 2230-2237.
29. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230.
30. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 43(6): 2163-2177.
31. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11): 1779-1802.
32. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee T-Y, Mayr NA, Parker GJM, Port R, Taylor JS, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3): 223-232.
33. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 17(2): 357-367.
34. Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman 3rd BB, Stewart CF (2014) Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 20(10): 2783-2792.
35. Verstraete KL, Lang P (2000) Bone and soft tissue tumors: The role of contrast agents for MR imaging. Eur Radiol 34: 229-246.
36. Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics 1(6): 80-83.
37. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH (1998) The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 80(7): 1020-1033.
38. Ye Z, Zhu J, Tian M, Zhang H, Zhan H, Zhao C, Yang D, Li W, Lin N (2008) Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18FFDG-PET. Ann Nucl Med 22(6): 475-480.